Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;52(12):919-928.
doi: 10.1159/000520028. Epub 2021 Nov 23.

Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017

Julie M Paik  1   2   3   4 , Min Zhuo  1   2   4   5 , Cassandra York  1 , Theodore Tsacogianis  1 , Seoyoung C Kim  1   4   6 , Rishi J Desai  1   4
Affiliations

Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017

Julie M Paik et al. Am J Nephrol. 2021.

Abstract

Introduction: The medication burden of patients with end-stage renal disease (ESRD) on hemodialysis, a patient population with a high comorbidity burden and complex care requirements, is among the highest of any of the chronic diseases. The goal of this study was to describe the medication burden and prescribing patterns in a contemporary cohort of patients with ESRD on hemodialysis in the USA.

Methods: We used the United States Renal Data System database from January 1, 2013, and December 31, 2017, to quantify the medication burden of patients with ESRD on hemodialysis aged ≥18 years. We calculated the average number of prescription medications per patient during each respective year (January-December), number of medications within classes, including potentially harmful medications, and trends in the number of medications and classes over the 5-year study period.

Results: We included a total of 163,228 to 176,133 patients from 2013 to 2017. The overall medication burden decreased slightly, from a mean of 7.4 (SD 3.8) medications in 2013 to 6.8 (SD 3.6) medications in 2017. Prescribing of potentially harmful medications decreased over time (74.0% with at least one harmful medication class in 2013-68.5% in 2017). In particular, the prescribing of non-benzodiazepine hypnotics, benzodiazepines, and opioids decreased from 2013 to 2017 (12.2%-6.3%, 23.4%-19.3%, and 60.0%-53.4%, respectively). This trend was consistent across subgroups of age, sex, race, and low-income subsidy status.

Conclusions: Patients with ESRD on hemodialysis continued to have a high overall medication burden, with a slight reduction over time accompanied by a decrease in prescribing of several classes of harmful medications. Continued emphasis on assessment of appropriateness of high medication burden in patients with ESRD is needed to avoid exposure to potentially harmful or futile medications in this patient population.

Keywords: End-stage kidney disease; End-stage renal disease; Hemodialysis; Medication burden; Prescribing patterns; United States Renal Data System.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

The authors report no conflicts of interest. R.J.D. reports serving as principal investigator on research grants from Bayer, Novartis, and Vertex to the Brigham and Women’s Hospital for unrelated projects. The authors confirm that the results presented in this manuscript have not been published previously in whole or part, except in the abstract format.

Figures

Fig. 1.
Fig. 1.
Mean number of medications by age, sex, race, and low-income subsidy status, 2013–2017.
Fig. 2.
Fig. 2.
Percentage with opioid prescription by age, sex, race, and low-income subsidy status, 2013–2017.
See this image and copyright information in PMC

References

    1. United States Renal Data System. 2020 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
    1. Pai AB, Cardone KE, Manley HJ, St Peter WL, Shaffer R, Somers M, et al. Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach. Clin J Am Soc Nephrol. 2013. Nov; 8(11):1988–99. - PMC - PubMed
    1. Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant. 2015. Jan;30(1):39–44. - PubMed
    1. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004. Jul;19(7):1842–8. - PubMed
    1. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009. Jun;4(6):1089–96. - PMC - PubMed

Publication types